Abstract: Formulations and methods for managing depression, anxiety and/or PTSD are described, for use by individuals in need thereof. The formulations comprise a plurality of cannabinoids and one or more excipient, diluent or carrier. The cannabinoids are present in the formulation in optimized amounts to address these conditions in an amount of: tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids in a weight ratio of from 0-1:4-20:10-25, respectively, such as 1:5:20, 0:20:10 or 0:10:20. Formulations and methods for aiding sleep are also described, for use by individuals in need thereof, such as individuals with insomnia. The formulation comprises a plurality of cannabinoids and one or more excipient, diluent or carrier. The formulation comprises tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids in a weight ratio of from 1:0-5:15-25, respectively, such as 1:3:20, 1:0:20 or 1:4:20.

Abstract: A formulation for pain management is described for use by individuals experiencing pain. The formulation comprises a plurality of cannabinoids in optimized amounts to manage pain. One or more excipient, diluent or carrier is included in the formulation. The types of pain to be managed with the formulation include but are not limited to the treatment of pain due to cancer, injury, accident, surgery, neuropathic pain or tissue damage. The primary cannabinoids are present in the formulation in amounts according to a ratio of THC:CBC:CBD ranging from 5:5:5 to 5:1:5. Methods of use of the formulation, doses and dosage forms are described which may have 5:5:5 mg or more of CBD:CBC:THC are described.

Abstract: A method of opioid sparing in a subject in need of pain management is described. The method comprises administering an effective amount of a formulation consisting of tetrahydrocannabinol (THC), cannabichromene (CBC), cannabidiol (CBD) and excipients; wherein the weight % ratio of THC:CBC:CBD is 1:1:1. In one embodiment, the 1:1:1 formulation can be used in conjunction with an additional formulation containing CBC:CBD at 1:5 to 5:5 weight %, for use at certain times of day when psychoactive effects of THC are not desired. Then at other times of day, the formulation comprising THC, CBC, and CBD can be used, for example at evening or bedtime. In some embodiments, the subject is one who has previously been administered an opioid medication for pain management, and the administration of the formulation is concomitant with a reduction in the administration of the opioid medication.

Abstract: A method of pain management is described, for use by individuals experiencing pain from musculoskeletal pain, osteoarthritis, and/or joint pain, including pain attributable to inflammation, comprising administration of a formulation comprising a plurality of cannabinoids. Primary cannabinoids are present in the formulation in amounts according to a weight ratio of THC:CBC:CBD ranging from 5:5:5 to 5:1:5. Methods of using the formulation, doses and dosage forms are described, including a formulation pairing in which a first formulation comprising CBC:CBD at 1:5 to 5:5 is utilized at certain times of day when psychoactive effects of THC are not desired, and a second formulation comprising THC:CBC:CBD is used at other times of day, typically evening or bedtime.

Abstract: A method of pain management is described, for use by individuals experiencing pain, comprising administration of a formulation comprising a plurality of cannabinoids. Primary cannabinoids are present in the formulation in amounts according to a weight ratio of THC:CBC:CBD ranging from 5:5:5 to 5:1:5. Methods of using the formulation, doses and dosage forms are described, including a formulation pairing in which a first formulation comprising CBC:CBD at 1:5 to 5:5 is utilized at certain times of day when psychoactive effects of THC are not desired, and a second formulation comprising THC:CBC:CBD is used at other times of day, typically evening or bedtime.

Abstract: A formulation for pain management is described for use by individuals experiencing pain. The formulation comprises a plurality of cannabinoids in optimized amounts to manage pain. One or more excipient, diluent or carrier is included in the formulation. The types of pain to be managed with the formulation include but are not limited to the treatment of pain due to cancer, injury, accident, surgery, neuropathic pain or tissue damage. The primary cannabinoids are present in the formulation in amounts according to a ratio of THC:CBC:CBD ranging from 5:5:5 to 5:1:5. Methods of use of the formulation, doses and dosage forms are described which may have 5:5:5 mg or more of CBD:CBC:THC are described.

Abstract: A system and method for recycling metals from industrial waste using an electrodepositing technique. The method includes the steps of collecting the industrial waste, transporting, processing and digesting the waste in a solvent or acidic solution and then electrodepositing out the desired metals. Other processing steps may be used to prepare the industrial waste for electrodeposition and the process may be repeated on the digest solution, to obtain multiple metals.